Subscribe to our Newsletters !!
HiGenoMB® Molecular Biology Division o
Telstar has developed a new sensor capable of moni
The virus outbreak i.e. monkey pox, has off late b
Micromeritics announced three significant new inve
Alembic Pharmaceuticals Limited (Alembic) today an
Following the success of the promotion and informa
Chromogenic culture media are used to isolate, ide
Mumbai, 28th December 2021: As countries prepare themselves to fight a possible ‘next wave’. The new variant – Omicron has been making headline and a surge in covid 19 cases are evident. According to a study based on population-level evidence, the recently identified Omicron variant of SARS-CoV-2 is associated with a substantial ability to evade immunity from prior Covid-19 infection. Omicron is also considered to be three times more transmissible than the Delta variant.
We cannot ignore the worst possible threat the new variant poses. In this continuous fight against the Covid 19, many scientists and pharma companies have come together and are working relentlessly to transform the Covid 19 treatment. Amongst many treatment options available, Molnupiravir is drawing attention amongst the medical fraternity.
Molnupiravir has been developed by Ridgeback in collaboration with the pharmaceutical giant Merck & Co. The pill has been cleared by regulators in Denmark, Philippines and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to treat mild-to-moderate COVID-19 in adults. Keeping in mind the high-risk population that may progress to severe disease, the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted 13 to 10 to recommend emergency authorization of Molnupiravir for the treatment of mild to moderate COVID-19 in adults.
It could be soon authorized for similar use in India. The drug may prove to be a game changer as it will aid in preventing the infections from worsening. It is easy to take at home as it is an oral anti-viral pill to, especially with the Omicron variant quickly spreading, drug may play important role in delaying the spread of Covid 19.
According to Dr P. P. Bose, Senior Consultant Pulmonologist National Heart Institute and Fortis CDOC, New Delhi and President, Saans Foundation stated, “Molnupiravir demonstrated consistent efficacy across viral variants and has shown promising results. The drug helps reducing the number of hospitalizations/deaths in patients with mild to moderate disease at risk of progression to severe disease. The drug may be instrumental in stopping the spread of Covid-19 infections and possible worsening of the condition. Entire doctor community is awaiting a final nod from the Indian regulator to use the drug. Molnupiravir approval can be significant in offering an affordable oral drug to treat Covid 19 in India. Since the pill will be produced and manufactured by a handful of pharma companies, it will be available under different brand names. For instance, Cipla is bringing it under the name of Cipmolnu.”